Skip to main content

Tulevik | Life Sciences Deal Intelligence & M&A Advisory

Our team

Two principals. Every engagement is run by one of them.

Home  / About Tulevik  / Our team

Principals

Tulevik is led by two principals with more than forty years of combined life sciences transaction experience. Every engagement is run by a principal — not delegated to a junior team — and supported by analysts and specialist consultants selected for the specific mandate.

Kiirsten L. Suurkask, Founder and President, Tulevik

Kiirsten L. Suurkask

Founder and President

Pharma services M&A · CDMO strategy · Operational diligence

Kiirsten founded Tulevik in 2017 to bring asset-level manufacturing intelligence into life sciences transactions — the operating detail that conventional deal advisory tends to treat as a footnote. She developed the firm’s Next-Gen Deal Intelligence methodology, which integrates manufacturing asset data with transaction analytics.

Over twenty years she has directed more than 100 pharma services and manufacturing transactions and led over 40 operational and supply chain due diligence engagements for private equity sponsors, strategic buyers, and founder-led platforms. She has evaluated manufacturing across biologics, aseptic fill-finish, vaccines, advanced therapies, and APIs, and has led consolidation-versus-divestiture analysis for multi-site organisations.

Before Tulevik she was a Partner at PharmaBioSource, where she led the pharma services M&A advisory practice and built the internal analytics team behind its manufacturing and lab asset intelligence tools. She also serves as Partner in the Pharma Services and M&A practice at Expert Insights Consulting.

M.B.S., Keck Graduate Institute of Applied Life Science · A.B. Biology, Harvard University DCAT · PDA · ISCT · Life Sciences BC

Kiirsten played varsity hockey at Harvard, where the team won a Division 1 national championship, and represented Canada at national junior level.
Linkedin
Alain T. Suurkask, Chief Commercial and Innovation Officer, Tulevik

Alain T. Suurkask

Chief Commercial and Innovation Officer

Growth strategy · Corporate and business development · Carve-out diligence

Alain leads Tulevik’s growth strategy and commercial work, advising clients on market entry, competitive positioning, and where to place capital. He joined the firm in 2020.

He has led or supported more than 25 transactions with combined enterprise value above $500 million, working with private equity sponsors, strategic acquirers, and executive teams across North America, Europe, and Latin America. At Tulevik he has run three sell-side mandates and led the evaluation of an under-utilised client asset, delivering board-level recommendations across transformation, joint venture, and disposition pathways.

His background spans both sides of the table. Before life sciences advisory he co-founded and served as a board member of a commercial renewable energy company, and spent a decade advising founders and executive teams on organic and inorganic growth. That operating experience shapes how he assesses underperforming assets. He also serves as Partner in the Pharma Services and M&A practice at Expert Insights Consulting.

B.S. Microbiology, University of British Columbia · Harvard Business School, CORe ISCT · PDA · AAPS · BIO · Life Sciences BC · DCAT

Alain played ice hockey at UBC and served as Vice-President of the university’s Athletic Student Council.
Linkedin

How we staff engagements

Every Tulevik engagement is led by a principal from first conversation to close. Around that core we build a team sized to the mandate — analysts for research and modelling, and specialist consultants brought in for specific technical, regulatory, or geographic requirements. The model is deliberate. Large advisory firms staff deep pyramids and bill the layers; the senior people who win the mandate are rarely the ones who run it. We keep the senior judgement on the work and scale the support around it, which means you pay for the expertise you need and speak to the people doing the analysis. For mandates that require broader coverage, we team with other advisory firms rather than stretching. We will tell you when that is the right structure, and who else is at the table.
Extended network
We draw on a bench of specialist consultants and analysts assembled over two decades in the sector. Depending on the mandate, that includes:
Capability Drawn in for
GMP manufacturing and quality Site assessments, capability evaluation, remediation exposure
Regulatory affairs Approval pathway risk, inspection history, filing portfolios
Financial modelling and valuation Underwriting support, scenario analysis, contract economics
Supply chain and logistics Network assessment, cold chain, single-source exposure
Commercial and market research Primary research, competitive benchmarking, demand modeling